Searched over 200M research papers
10 papers analyzed
These studies suggest metformin can lead to weight loss in non-diabetic individuals, but more large-scale trials are needed to confirm its effectiveness in this population.
20 papers analyzed
Metformin, a widely used antidiabetic medication, has garnered attention for its potential benefits in weight management, even among non-diabetic individuals. This article synthesizes findings from various studies to explore the efficacy and mechanisms of metformin-induced weight loss in non-diabetic populations.
Several clinical trials have demonstrated that metformin can lead to significant weight loss in non-diabetic individuals. A randomized double-blind clinical trial involving non-diabetic obese women showed that metformin, combined with a low-calorie diet, resulted in a 4.5% decrease in BMI over two months, compared to a 2.6% decrease in the placebo group. Another study highlighted that metformin led to weight reductions of 1-5 kg in both diabetic and non-diabetic obese patients.
The mechanisms behind metformin-induced weight loss are multifaceted. One study found that while the overall gut microbiota composition remained largely unchanged, there was a significant increase in specific bacterial groups such as Escherichia/Shigella in the metformin group. Additionally, metformin has been shown to increase the secretion of Growth Differentiation Factor 15 (GDF-15), which binds to the GFRAL receptor in the brain, reducing food intake and body weight.
Long-term studies have confirmed the safety and sustained efficacy of metformin for weight loss. The Diabetes Prevention Program Outcomes Study reported that metformin use led to a durable weight loss of about 2% over a 10-year period, with the degree of weight loss being directly related to adherence to the medication. Another meta-analysis focusing on elderly patients found a small but significant reduction in body weight and improvements in lipid profiles, suggesting that metformin is a safe option for long-term use in older populations.
A systematic review of multiple trials indicated that metformin consistently led to weight loss in both adults and adolescents without diabetes, although the studies were often limited by small sample sizes and weak designs. Another review found that metformin was effective in reducing weight and improving metabolic parameters such as waist circumference, fasting insulin, and glucose levels.
Metformin appears to be a promising pharmacological option for weight loss in non-diabetic individuals. Its efficacy is supported by multiple clinical trials and long-term studies, which also highlight its safety and tolerability. The weight loss effects are likely mediated through changes in gut microbiota and the GDF-15 pathway. However, further large-scale, well-designed trials are needed to firmly establish its role in weight management for non-diabetic populations.
Most relevant research papers on this topic